Morn­ing­side re­veals its lat­est biotech ef­fort, seek­ing to tack­le wide range of in­flam­ma­to­ry dis­eases

Morn­ing­side Ven­tures un­veiled its lat­est bet Thurs­day morn­ing, one where it’s al­ready pro­vid­ed more than $60 mil­lion in cash.

The VC firm un­veiled Adiso Ther­a­peu­tics on Thurs­day, a Con­cord, MA-based biotech aim­ing to tack­le a wide va­ri­ety of in­flam­ma­to­ry dis­eases. Adiso launched with two com­pounds al­ready in the clin­ic and a third can­di­date still in pre­clin­i­cal stud­ies. The ini­tial fo­cus­es are ul­cer­a­tive col­i­tis and C. dif­fi­cile in­fec­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER